石藥集團(01093.HK)2023年營收穩增至314.5億元 純利達58.73億元
格隆匯3月20日丨石藥集團(01093.HK)公佈，截至2023年12月31日止年度，集團收入為人民幣314.50億元，較2022年增加1.7%。撇除按公平值計入損益的金融資產的公平值變動、以股份為基礎的僱員酬金開支及視作出售聯營公司及合營企業部分權益的收益，股東應占基本溢利為人民幣62.75億元，較2022年增加2.8%。股東應占溢利為人民幣58.73億元。董事會建議派發2023年度末期股息每股14港仙。
2023年，集團始終堅持「強創新，強團隊，強管理，穩增長」的經營方針，在追求持續提高競爭力的同時，實現了業績的穩定增長。2023年成藥業務保持穩定增長，多個近年新增的產品如明覆樂®(注射用重組人TNK組織型纖溶酶原激活劑)、伊絡達®(乙磺酸尼達尼布軟膠囊)及安複利克®(注射用兩性黴素B膽固醇硫酸酯複合物)等均於年內快速上量。此外，多個具有市場潛力的新藥獲批上市，其中包括津立泰®(納魯索拜單抗注射液)、多恩益®(鹽酸伊立替康脂質體注射液)及歐悦欣®(琥珀酸地文拉法辛緩釋片)，第三代特異性溶栓藥物明覆樂®用於治療急性缺血性卒中亦於2024年2月獲得上市批准。多恩達®(鹽酸米託蒽醌脂質體注射液)、克必妥®(度維利塞膠囊)、海益坦®(谷美替尼片)和歐悦欣®順利通過了醫保談判納入國家醫保目錄 。
集團於年內繼續加大研發的投入，同時研發效率持續提升。創新藥物的研發和臨牀開發都按計劃推進，目前有逾60個重點候選產品已處於臨牀階段，當中有多個為具有全球專利且極具市場價值的重磅產品。新產品的獲批和持續上量為本集團銷售收入的增長奠定了堅實的基礎，並使集團在各個治療領域的產品佈局更加均衡。
集團於年內加快推進國際化的步伐，在新加坡建立國際總部及製劑海外市場事業部，致力加快脂質體等高端複雜製劑、單雙抗體等生物製劑在歐、美、日韓等市場的拓展工作；在亞非拉國開展多種類型製劑的註冊及客户開發工作；及在「一帶一路」沿線國家如新加坡、泰國、馬來西亞和越南設立公司，推動產品註冊和銷售工作，提高海外業務的貢獻。
在業務拓展方面，集團於本年完成3個重大產品授權項目。其中與美國Corbus Pharmaceuticals,Inc.簽訂的SYS6002 (Nectin-4 ADC)獨家授權協議標誌着集團的創新能力受到國際認可，是集團自研創新產品出海的重要里程碑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
